DCT Board Approves Continuing Neutron Trials Pas 1989 Expiration, With New Funding Plan
In Brief: Interim Dean Henney Looking for Cancer Center Director; Shingleton Gets James Ewing Award
Collaborative Drug Development Groups Clear BSC Overview, Natural Products RFA To Proceed
Curt, Ozols, Brown Leaving NCI; More DCT Staff Changes
DCT Board Approves Two RFAs, Changes One To PA, Kills One On Liposomes
Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures - In weekly vigils, current and former NIH staff grieve the impact of Trump cuts
The Saturday gatherings at NIH’s Metro station are part graveside service, part street theater - She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- Scaling excellence: How City of Hope is transforming cancer care delivery
- First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI